This website is intended for Healthcare Professionals practicing in the U.S.

Building a better understanding of hypochondroplasia

Hypochondroplasia is a rare and heterogeneous condition that impacts health, function, and daily life for patients and their families.1,2

Stay updated on hypochondroplasia

Sign up to receive information about hypochondroplasia care, educational resources, and the latest research sent directly to your inbox.

Sign up

What is hypochondroplasia?

Hypochondroplasia is a rare genetic skeletal dysplasia that inhibits bone growth throughout the body.1,3-7

The effects of the condition can include disproportionate short stature, functional limitations, and potential multisystemic complications, all of which can vary in severity from person to person and can adversely affect quality of life.1,2,7-11

Medical graphic showing bones with inhibited growth from hypochondroplasia, a rare genetic skeletal dysplasia.

The effects of hypochondroplasia

Bone growth occurs for a limited time—before birth until late adolescence/early adulthood. In hypochondroplasia, a signaling imbalance in cartilage cells causes endochondral bone growth to be inhibited throughout the body.1,4-7,12,27,28

Early recognition for timely intervention

Children with short stature (>2 standard deviations below the mean) who also present with at least one of the following red flag* clinical features should be further evaluated for potential hypochondroplasia1,29-31:

  • Disproportionate growth
  • Relative macrocephaly
  • Midface hypoplasia (frontal bossing)
  • Short arms and legs (rhizomelia/mesomelia)
  • Bowed legs (genu varum)
  • Brachydactyly

If you observe any of these red flags, your patient’s diagnosis may go beyond short stature, and genetic testing may be necessary.1,31

*Red flags refer to clinical features that may raise suspicion for hypochondroplasia and prompt further evaluation, including consideration of genetic testing. Features shown are not intended to represent all possible manifestations.1,31

Early confirmation of a hypochondroplasia diagnosis can help inform proactive approaches to care and improve patient outcomes.1

Multisystemic complications

Beyond the common clinical features, including disproportionate short stature, hypochondroplasia can be associated with multisystemic complications that can impact various aspects of health, development, and daily functioning.1,10,11

Skeletal

  • Relative macrocephaly
  • Scoliosis
  • Lumbar lordosis
  • Spinal stenosis
  • Genu varum

Otolaryngologic

  • Otitis media
  • Conductive hearing loss
  • Obstructive sleep apnea

Neurological

  • Neurological disorders (eg, epilepsy)
  • Neurocognitive issues
  • Intellectual disability
  • Hydrocephalus

Multisystemic complications can contribute to psychological stress, anxiety, and depression—each associated with lower patient- and caregiver-reported quality of life.1,8,32

The underlying genetic cause

Hypochondroplasia is caused by gain-of-function variants in the fibroblast growth factor receptor 3 (FGFR3) gene that lead to overactive FGFR3 signaling (slows bone growth) relative to C-type natriuretic peptide (CNP) signaling (promotes bone growth) in chondrocytes.1,27,33

  • The FGFR3 gene is expressed throughout the body (including the brain) but mainly functions as a negative regulator of endochondral bone growth (cartilage developing into bone)4
  • Heterogeneous genetic profile: The N540K variant in the intracellular tyrosine kinase domain of FGFR3 is the most common pathogenic variant (accounts for ~50%-70% of hypochondroplasia cases), but a broad spectrum of variants are also associated with the condition, with more being discovered1,33,34
  • Most cases result from a spontaneous de novo genetic change, with a minority inheriting the gene variant from one or both parents through an autosomal dominant pattern1
Medical graphic of the imbalance between FGFR3 and CNP cell signaling leading to inhibited bone growth.

Hypochondroplasia care begins with confirmation

Due to its heterogeneous presentation and overlapping symptoms with other skeletal conditions, hypochondroplasia can often be underrecognized or misdiagnosed. Delayed diagnosis of skeletal dysplasias can prevent healthcare professionals from educating caregivers on what health impacts to expect from a specific condition and identifying opportunities for proactive care.1,2,30,35

No-charge genetic testing

Healthcare providers can learn more about the Discover Dysplasias™ program, which offers sponsored genetic testing and counseling for eligible individuals 16 years of age or younger suspected of having a skeletal dysplasia.

Visit the Discover Dysplasias™ website to learn more

Specialized care for unique health needs

Management of hypochondroplasia may require proactive and lifelong care by a multidisciplinary team to help address unique health needs. Timely and experienced care can meaningfully contribute to positive patient outcomes.1,30

The foundation of patient care should include growth specialists to identify health needs specific to hypochondroplasia, pediatricians to track development and help families navigate adaptive interventions, along with other specialties to address health complications that may arise and change throughout development.1,7

The latest hypochondroplasia research and clinical developments

Currently there are no FDA-approved treatments for hypochondroplasia that target the cause of inhibited bone growth. Existing treatment options, such as supportive care or surgeries, focus on the management of symptoms. However, there are clinical trials currently underway that may soon offer more options for care.1,3,27

Sign up to receive updates

Hypochondroplasia resources

Download helpful tools and educational materials for additional information about hypochondroplasia.

Hypochondroplasia: A guide for parents

A collection of insights and experiences of families living with hypochondroplasia.2

Download

Hypochondroplasia information sheet

Information on how hypochondroplasia occurs, common complications, and the importance of specialized care.1

Download

Stay updated on hypochondroplasia

Sign up to receive information about hypochondroplasia care, management approaches, and the latest research sent directly to your inbox.

*Required fields

References

  1. Bober MB, Bellus GA, Cheung MS, et al. Hypochondroplasia. In GeneReviews® [Internet]. 1999 (updated September 25, 2025). Accessed May 14, 2026. https://www.ncbi.nlm.nih.gov/books/NBK1477/
  2. Oehrlein EM, Pekala R, Cavallaro S, et al. Living with hypochondroplasia: a qualitative exploration of children’s and caregivers’ experiences, challenges, and unmet needs. Mol Genet Genomic Med. 2025;13(11):e70151.
  3. Kim HY, Ko JM. Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood. Ann Pediatr Endocrinol Metab. 2022;27(2):90-97.
  4. Foldynova-Trantirkova S, Wilcox WR, Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat. 2012;33(1):29-41.
  5. Mackie EJ, Tatarczuch L, Mirams M. The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol. 2011;211(2):109-121.
  6. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3(Suppl 3):S131-S139.
  7. Cheung MS, Cole TJ, Arundel P, et al. Growth reference charts for children with hypochondroplasia. Am J Med Genet A. 2024;194(2):243-252.
  8. Fagereng E, Htwe S, McDonald S, et al. Mental health conditions, physical functioning, and health-related quality of life in adults with a skeletal dysplasia: a cross-sectional multinational study. Orphanet J Rare Dis. 2025;20(1):116.
  9. Galetaki D, Zhang A, Rangos N, et al. Parental perception of quality of life and impact of short stature in children with hypochondroplasia and other genetic causes of short stature. Horm Res Paediatr. 2025;17:1-9.
  10. Doherty M, Hertel NT, Hove HB, et al. Neurological symptoms, evaluation and treatment in Danish patients with achondroplasia and hypochondroplasia. J Rare Dis Res Treat. 2017;2:25-32.
  11. Linnankivi T, Mäkitie O, Valanne L, Toiviainen-Salo S. Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation. Am J Med Genet A. 2012;158A(12):3119-3125.
  12. Breeland G, Sinkler MA, Menezes RG. Embryology, bone ossification. In: StatPearls. StatPearls Publishing; 2023. Accessed May 14, 2026. https://www.ncbi.nlm.nih.gov/books/NBK539718/
  13. Berendsen AD, Olsen BR. Bone development. Bone. 2015;80:14-18.
  14. Johns Hopkins Medicine. Anatomy of the bone. Accessed May 14, 2026. https://www.hopkinsmedicine.org/health/wellness-and-prevention/anatomy-of-the-bone
  15. Jin SW, Sim KB, Kim SD. Development and growth of the normal cranial vault: an embryologic review. J Korean Neurosurg Soc. 2016;59(3):192-196.
  16. Encyclopaedia Britannica. Science & Tech. Clavicle. Accessed May 14, 2026. https://www.britannica.com/science/clavicle
  17. Encyclopaedia Britannica. Science & Tech. Skull. Accessed May 14, 2026. https://www.britannica.com/science/skull
  18. Hall R, Beals K, Neumann H, et al. Introduction to Human Osteology. Grand Valley State University; 2008.
  19. Anderson BW, Kortz MW, Black AC, et al. Anatomy, head and neck, skull. In: StatPearls. StatPearls Publishing; 2023. Accessed May 14, 2026. https://www.ncbi.nlm.nih.gov/books/NBK499834/
  20. Cowan PT, Launico MV, Kahai P. Anatomy, bones. In: StatPearls. StatPearls Publishing; 2024. Accessed May 14, 2026. https://www.ncbi.nlm.nih.gov/books/NBK537199/
  21. Hsieh YL, Wei X, Wang Y, et al. Chondrocyte Tsc1 controls cranial base bone development by restraining the premature differentiation of synchondroses. Bone. 2021;153:116142.
  22. Musculoskeletal Key. Cranial and pelvic “vertebrae” are they real vertebrae? Accessed May 14, 2026. https://musculoskeletalkey.com/cranial-and-pelvic-vertebrae-are-they-real-vertebrae/
  23. Young M, Selleri L, Capellini TD. Genetics of scapula and pelvis development: an evolutionary perspective. Curr Top Dev Biol. 2019;132:311-349.
  24. Yu M, Wang SM. Anatomy, head and neck, ethmoid bone. In: StatPearls. StatPearls Publishing; 2025. Accessed May 14, 2026. https://www.ncbi.nlm.nih.gov/books/NBK544328/
  25. Çankaya H, Egeli E, Kutluhan A, Kiriş M. Pneumatization of the concha inferior as a cause of nasal obstruction. Rhinology. 2001;39(2):109-111.
  26. Mitomo K, Matsunaga S, Kitamura K, et al. Sphenoid bone hypoplasia is a skeletal phenotype of cleidocranial dysplasia in a mouse model and patients. Bone. 2019;120:176-186.
  27. Allen DB, Merchant N, Miller BS, Backeljauw PF. Evolution and future of growth plate therapeutics. Horm Res Paediatr. 2021;94(9-10):319-332.
  28. Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91(6):1108-1114.
  29. Sharma L, Rani D, Kanchan T, Krishan K. Short stature. In: StatPearls. StatPearls Publishing; 2026. Accessed May 14, 2026. https://pubmed.ncbi.nlm.nih.gov/32310491/
  30. Sabir AH, Sheikh J, Singh A, et al. Earlier detection of hypochondroplasia: a large single-center UK case series and systematic review. Am J Med Genet A. 2021;185(1):73-82.
  31. Data on file [1]. BioMarin Pharmaceutical Inc; 2025.
  32. Rangos N, Dwivedi P, Boucher K, et al. Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting [Abstract 6206]. Horm Res Paediatr. 2023;96(suppl 3):195-197.
  33. Irving M, Greco E, Cocca A, et al. Pathways to facilitate early recognition and diagnosis of hypochondroplasia. Adv Ther. 2026;43(5):2018-2033.
  34. Ramos Mejía R, Aza-Carmona M, Del Pino M, et al. Clinical and radiologic evaluation of an individual with hypochondroplasia and a novel FGFR3 mutation. J Pediatr Genet. 2020;9(1):48-52.
  35. Meyer MF, Menken KU, Zimny S, Hellmich B, Schatz H. Pitfall in diagnosing growth hormone deficiency in a hypochondroplastic patient with a delayed puberty. Exp Clin Endocrinol Diabetes. 2003;111(3):177-181.